الولايات المتحدة · وكالات وأخبار لحظية · PR Newswire

Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial.

نشره PR Newswire · الولايات المتحدة منذ 4 س

SHANGHAI, Oct. 31, 2026 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ( "Zhimeng Biopharma") announced today that its independently developed next-generation potassium channel…

اقرأ المقال كاملًا على PR Newswire سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.prnewswire.com)

يستحق القراءة أيضًا

Associated Press (Business)

Brazil summons Argentina’s representative after Bolsonaro flees to the US via Argentina

Business Wire

Fujifilm to Increase Production Capacity by 5x for Magnetic Data Storage Tape

Dow Jones Newswires

Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial.

مشاركة

يستحق القراءة أيضًا

Brazil summons Argentina’s representative after Bolsonaro flees to the US via Argentina

Fujifilm to Increase Production Capacity by 5x for Magnetic Data Storage Tape

How Dow Jones Is Covering the U.S. Midterms